Eubel Brady & Suttman Asset Management’s AbbVie ABBV Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$385K	Buy	1,530 +530	+53%	+$114K	0.05%	89
2026 Q1	$217K	Hold	1,000	–	–	0.03%	111
2025 Q4	$228K	Sell	1,000 -27	-3%	-$6.15K	0.03%	111
2025 Q3	$238K	Buy	+1,027	New	+$209K	0.03%	108
2025 Q2	–	Sell	-1,029	Closed	-$216K	–	98
2025 Q1	$216K	Buy	+1,029	New	+$200K	0.03%	90
2024 Q4	–	Sell	-1,038	Closed	-$205K	–	91
2024 Q3	$205K	Sell	1,038 -676	-39%	-$126K	0.03%	88
2024 Q2	$294K	Buy	+1,714	New	+$284K	0.04%	79
2021 Q3	–	Sell	-831	Closed	-$90K	–	72
2021 Q2	$90K	Buy	+831	New	+$93.6K	0.01%	262
2017 Q1	–	Sell	-5,507	Closed	-$345K	–	76
2016 Q4	$345K	Hold	5,507	–	–	0.1%	62
2016 Q3	$347K	Sell	5,507 -210	-4%	-$13.6K	0.11%	61
2016 Q2	$354K	Sell	5,717 -325	-5%	-$19.8K	0.12%	55
2016 Q1	$345K	Hold	6,042	–	–	0.12%	55
2015 Q4	$358K	Buy	6,042 +100	+2%	+$5.76K	0.12%	56
2015 Q3	$323K	Hold	5,942	–	–	0.11%	56
2015 Q2	$399K	Hold	5,942	–	–	0.13%	49
2015 Q1	$348K	Sell	5,942 -120	-2%	-$7.25K	0.11%	54
2014 Q4	$397K	Buy	6,062 +195	+3%	+$12.3K	0.12%	49
2014 Q3	$339K	Sell	5,867 -280	-5%	-$15.5K	0.1%	63
2014 Q2	$347K	Hold	6,147	–	–	0.1%	54
2014 Q1	$316K	Buy	6,147 +325	+6%	+$16.4K	0.09%	63
2013 Q4	$307K	Buy	5,822 +83	+1%	+$4.08K	0.09%	60
2013 Q3	$257K	Hold	5,739	–	–	0.07%	72
2013 Q2	$237K	Buy	+5,739	New	+$251K	0.07%	74

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's ABBV Position: Q2 2026 in Review

Eubel Brady & Suttman Asset Management increased its AbbVie (ABBV) stake by 53% in Q2 2026, buying an estimated $114K and bringing the position to 1,530 shares worth $385K. The position accounts for 0.05% of the portfolio, ranked #89.

Eubel Brady & Suttman Asset Management first reported a position in ABBV in Q2 2013 and has held it in 23 quarters since. The position peaked at $399K in Q2 2015. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Eubel Brady & Suttman Asset Management held 1,530 shares of AbbVie worth $385K as of Q2 2026.
Eubel Brady & Suttman Asset Management bought 530 AbbVie shares in Q2 2026, an estimated $114K.
AbbVie made up 0.05% of Eubel Brady & Suttman Asset Management's portfolio in Q2 2026, its #89 holding.
Eubel Brady & Suttman Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 23 quarters since.
Eubel Brady & Suttman Asset Management's AbbVie position peaked at $399K in Q2 2015.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.